QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 内容类型：期刊论文    专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review 期刊论文 JOURNAL OF ONCOLOGY, 2022, 卷号: 2022 作者:  Hu, Shumin;  Gong, Jiali;  Zhu, Xiu;  Lu, Hongyang 收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23 The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study 期刊论文 CANCERS, 2022, 卷号: 14 作者:  Xie, Mingying;  Li, Na;  Xu, Xiaoling;  Xu, Yanjun;  Li, Hui 收藏  |  浏览/下载：23/0  |  提交时间：2022/12/22 liver metastasis  non-small cell lung cancer  PD-L1  PD-1  PD-L1 inhibitor  CD8+T cell   Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study 期刊论文 GENES CHROMOSOMES & CANCER, 2022 作者:  Wang, Wenxian;  Gu, Xiaodong;  Si, Jinfei;  Pu, Xingxiang;  Wang, Liping 收藏  |  浏览/下载：31/0  |  提交时间：2022/05/16 BRAF mutation  immune checkpoint inhibitors  non-small cell lung cancer  PD-L1  targeted therapy   Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer 期刊论文 JOURNAL OF ONCOLOGY, 2022, 卷号: 2022 作者:  Li, Yue;  Li, Chong;  Jiang, Ya;  Han, Xue;  Liu, Sisi 收藏  |  浏览/下载：15/0  |  提交时间：2022/12/23 High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文 BMC CANCER, 2022, 卷号: 22 作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao 收藏  |  浏览/下载：43/0  |  提交时间：2022/02/14 Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment   A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer 期刊论文 FRONTIERS IN IMMUNOLOGY, 2021, 卷号: 12 作者:  Peng, Jie;  Zou, Dan;  Han, Lijie;  Yin, Zuomin;  Hu, Xiao 收藏  |  浏览/下载：23/0  |  提交时间：2022/02/14 non-small cell lung cancer  support vector machine  major pathological response  liquid immune profiling  neoadjuvant treatment   AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun 收藏  |  浏览/下载：32/0  |  提交时间：2022/01/10 The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis 期刊论文 CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15 - 收藏  |  浏览/下载：7/0  |  提交时间：2020/10/26 PD-L1 EXPRESSION  POOR  CANCER  Meta-analysis  non-Hodgkin lymphoma (NHL)  programmed cell death ligand 1 (PD-L1)  prognosis